ALEXION PHARMACEUTICALS, INC.

ALEXION PHARMACEUTICALS, INC. logo
🇺🇸United States
Ownership
Public, Subsidiary
Established
1992-01-01
Employees
3.8K
Market Cap
-
Website
http://www.alexion.com
Clinical Trials
Related News

A Drug Interaction Study of Danicopan

First Posted Date
2021-01-14
Last Posted Date
2021-01-14
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
52
Registration Number
NCT04709094
Locations
🇺🇸

Clinical Study Site, Tempe, Arizona, United States

A Study of the Cardiac Effects of ALXN2050 in Healthy Adults

First Posted Date
2020-12-09
Last Posted Date
2021-12-29
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
39
Registration Number
NCT04660890
Locations
🇺🇸

Clinical Trial Site, Tempe, Arizona, United States

Study of ALXN1820 in Healthy Adult Participants

First Posted Date
2020-11-17
Last Posted Date
2024-08-20
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
66
Registration Number
NCT04631562
Locations
🇬🇧

Research Site, London, United Kingdom

Study of ALXN2050 in Participants With Renal Impairment

Phase 1
Completed
Conditions
Healthy
Renal Impairment
Interventions
Drug: ALXN2050
First Posted Date
2020-11-10
Last Posted Date
2023-09-29
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
40
Registration Number
NCT04623710
Locations
🇺🇸

Clinical Trial Site, Orlando, Florida, United States

A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM

Phase 3
Active, not recruiting
Conditions
Symptomatic Transthyretin Amyloid Cardiomyopathy
Interventions
Drug: ALXN2060
First Posted Date
2020-11-09
Last Posted Date
2024-12-16
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
25
Registration Number
NCT04622046
Locations
🇯🇵

Research Site, Suita-shi, Japan

Bioavailability Study of 2 Oral Formulations of ALXN1840

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: ALXN1840
First Posted Date
2020-10-30
Last Posted Date
2024-01-16
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
48
Registration Number
NCT04610580
Locations
🇦🇺

Nucleus Network Pty Ltd., Melbourne, Victoria, Australia

Study of the Metabolism of Danicopan in Healthy Adults

Phase 1
Completed
Conditions
Healthy
First Posted Date
2020-10-30
Last Posted Date
2022-04-15
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
24
Registration Number
NCT04609696
Locations
🇺🇸

Clinical Trial Site, Tempe, Arizona, United States

Study of Radiolabeled ALXN2050 in Healthy Adult Males

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: [14C]-ALXN2050
First Posted Date
2020-10-30
Last Posted Date
2023-01-25
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
9
Registration Number
NCT04609670
Locations
🇺🇸

Clinical Trial Site, Lincoln, Nebraska, United States

Copper Balance in Healthy Participants Administered ALXN1840

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: ALXN1840
First Posted Date
2020-10-20
Last Posted Date
2024-08-19
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
17
Registration Number
NCT04594252
Locations
🇬🇧

Clinical Study Site, London, United Kingdom

Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840

Phase 2
Completed
Conditions
Wilson Disease
Interventions
Drug: ALXN1840
First Posted Date
2020-10-05
Last Posted Date
2024-06-24
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
9
Registration Number
NCT04573309
Locations
🇬🇧

Research Site, London, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy